Latest Feature

What's behind the slump in early-stage medtech investment?

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells MassDevice.com.

Kimberly-Clark readies Halyard Health medical device spinout

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

HART CEO David Green on the transformative potential for regenerative medicine

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Podcast: Medtech legends and leaders on the state of medical device innovation

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Studies criticize U.S. medical device approval process

September 29, 2014 by MassDevice

The FDA's less-stringent 510(k) clearance process comes under fire (again) in a pair of new studies.

Studies criticize U.S. medical device approval process

NEW YORK (Reuters Health) - Information on the safety and effectiveness of medical devices before and after they are cleared by U.S. health regulators can be improved, according to 2 new studies.

Tengion is on the auction block

September 29, 2014 by Alexander Soule

Tengion puts itself and its organ regeneration technology on the auction block, hiring Jefferies LLC to explore "strategic alternatives."

Tengion, TNGN, Jefferies, organ regeneration, kidney

YYmeta

Tengion (NSDQ:TNGN) said it's hired Jefferies to assess "all strategic alternatives," corporate shorthand for putting the Winston-Salem, N.C.-based company and its organ regeneration technology on the auction block.

Mitralign reports 1st-in-human tricuspid valve repair

September 29, 2014 by Alexander Soule

Mitralign reports the 1st-in-human use of its minimally invasive device to treat tricuspid valve regurgitation under a compassionate use allowance in Germany.

Mitralign reports 1st-in-human tricuspid valve repair

Mitralign said today that surgeons in Germany implanted its tricuspid valve repair device in its 1st patient, under a "compassionate use" allowance in Germany.

Cohealo raises $3m for medical device sharing software

September 29, 2014 by Alexander Soule

Cohealo reports a $3.2 million debt round for the software it's developing to help hospitals manage their shared medical device inventory.

Cohealo raises $3m for medical device inventory management solution

Cohealo reported raising $3.1 million of a hoped-for $5.8 million in debt financing as it develops software to help hospitals manage their shared medical device inventory.

MassDevice.com +3 | The top 3 medtech stories for September 29, 2014

September 29, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

CVRx wins heart failure CE Mark for Barostim Neo neurostim device

September 29, 2014 by Brad Perriello

CVRx adds CE Mark approval for treating heart failure patients to its European Union approval for hypertension treatment using its Barostim Neo device.

CVRx said today that it won CE Mark approval in the European Union for its Barostim Neo device to treat heart failure patients using vagus nerve stimulation.

What we've learned from four years of diving into dollars for docs

September 29, 2014 by MassDevice

Payments from pharmaceutical companies touch hundreds of thousands of doctors. The 17 companies we've tracked spent $1.4 billion in 2013 alone. Here are our top five takeaways from following all that money.

What We've Learned From Four Years of Diving Into Dollars for Docs

David Sleight/ProPublica

by Charles Ornstein, Eric Sagara and Ryann Grochowski Jones, ProPublica

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp